Home » Business » Manufacturing
Partners invest in R&D and production facility
By Ding Yining |
June 7, 2013, Friday
|
Print Edition
Print Edition
GERMAN pharmaceutical maker Boehringer Ingelheim and Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co will invest 500 million yuan (US$81.4 million) to build a research and development and manufacturing facility in Shanghai.
Boehringer Ingelheim said yesterday it will invest over 35 million euros (US$46 million) for the first phase of the facility which will be sited in the Zhangjiang High-tech Park in the Pudong New Area. The facility may become operational by early 2016.
The Zhangjiang Group will provide 150 million yuan in the form of land and factory in the first phase.
"Biopharmaceuticals, together with prescription medicines, consumer health care, animal health and manufacturing, will become the five pillars driving our business in China," said David Preston, chairman and chief executive officer of Boehringer Ingelheim China and Hong Kong.
The German company may also become the first multinational drug manufacturer to provide contract manufacturing services for local companies.
"The contract manufacturing facility is expected to lower production cost for smaller start-up companies and ease their capital pressure," said Wang Lanzhong, general manager of the Shanghai drug company. "It will also help to boost Shanghai's biopharmaceutical industry."
Boehringer Ingelheim said yesterday it will invest over 35 million euros (US$46 million) for the first phase of the facility which will be sited in the Zhangjiang High-tech Park in the Pudong New Area. The facility may become operational by early 2016.
The Zhangjiang Group will provide 150 million yuan in the form of land and factory in the first phase.
"Biopharmaceuticals, together with prescription medicines, consumer health care, animal health and manufacturing, will become the five pillars driving our business in China," said David Preston, chairman and chief executive officer of Boehringer Ingelheim China and Hong Kong.
The German company may also become the first multinational drug manufacturer to provide contract manufacturing services for local companies.
"The contract manufacturing facility is expected to lower production cost for smaller start-up companies and ease their capital pressure," said Wang Lanzhong, general manager of the Shanghai drug company. "It will also help to boost Shanghai's biopharmaceutical industry."
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
